Produktname:6-chloro-7H-purin-2-amine

IUPAC Name:6-chloro-7H-purin-2-amine

CAS:10310-21-1
Molekulare Formel:C5H4ClN5
Reinheit:98%
Katalognummer:CM105259
Molekulargewicht:169.57

Packungseinheit Verfügbarer Vorrat Preis($) Menge
CM105259-500g in stock ƩƩȋ
CM105259-1000g in stock ǺǺş

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

   refresh    

Produkt-Details

CAS-Nr.:10310-21-1
Molekulare Formel:C5H4ClN5
Schmelzpunkt:-
SMILES-Code:NC1=NC(Cl)=C2NC=NC2=N1
Dichte:
Katalognummer:CM105259
Molekulargewicht:169.57
Siedepunkt:
Mdl-Nr.:MFCD00075252
Lagerung:Protect form light and store in a dry and close container at room temperature

Category Infos

Purines
Purines are heterocyclic aromatic compounds composed of linked pyrimidine and imidazole rings. In mammals, purines are most commonly expressed in DNA and RNA (including the purines adenine and guanine), as well as single-molecule nucleotides (adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP), cyclic AMP, and to a lesser extent guanosine triphosphate (GTP) and cyclic guanosine monophosphate (cGMP). Purines are also key elements of the following energy metabolism molecules: reduced nicotinamide adenine dinucleotide, nicotinamide adenine dinucleotide phosphate (NADPH), and coenzyme Q. Purines can also act as direct neurotransmitters; for example, adenosine may interact with receptors to modulate cardiovascular and central nervous system (CNS) function.
purine wholesale
Find trusted purine wholesaler. Any requirements and problems can ask us at any time.
Nucleosides and Nucleotides
Nucleosides consist of a nucleotide and a five-carbon sugar, and a nucleotide consists of a nucleotide, a five-carbon sugar, and one or more phosphate groups.
nucleoside manufacturer
As a professional nucleoside manufacturer, we can guarantee product quality and delivery time.our company has been committed to supply personalized product solutions to customers,pls consult us.

Column Infos

Ibezapolstat
Acurx announces successful FDA end-of-phase 2 meeting and phase 3 readiness for Ibezapolstat in the treatment of C. difficile infection. The successful meeting outcomes include reaching key elements of Phase 3 clinical trial program and a development plan of NDA filling. C. difficile infection (CDI) is a bacterial infection of the colon, and causes diarrhea and colitis.
Ibezapolstat is a novel antibacterial agent that acts specially on DNA pol IIIC enzyme through competitive inhibition of dGTP (guanosine analog). Ibezapolstat has been granted Fast Track Designation from the U.S. FDA.